Translated by Google
Palatin Technologies to go - price target 6 USD?
Following our numerous multiplication tips in the biotech sector, our current industry advantage Palatin Technologies (WKN: A1C538) is now slowly starting. We had presented you the stock for the first time at a price of about 0.30 USD; meanwhile it is 50% higher. It is expected that Palatin will be reporting on the last fiscal year and the latest achievements as well as upcoming milestones on 19 September. It is quite possible that in the meantime we have already entered completely new course dimensions and that the overvaluated revaluation is in the middle of the course. In-line price catalysts are on the agenda at short notice. And even a takeover just now appears as a plausible scenario.
If you can not start the stock yet, we recommend that you read all our latest articles on the subject and form your own opinion. In fact, you will find: There can be no two opinions and the price target of 6 USD, which the renowned analysts of Canaccord last gave, is anything but utopia!
At the same time, there is also a blog entry for additional fire: The Pharmariese Merck is interested in Palatins before the authorization standing "lust" for the woman. Despite the significant underestimation of Palatins, we also advise caution to enjoy this speculation. The source of the information is not known. The fact is that Palmer's competitor drug Addyi, which has significant disadvantages against Palatin's bremelanotides, was purchased together with producer Sprout Pharmaceuticals in 2015 for $ 1 billion in cash plus milestone payments from the Canadian Valeant Group. On the basis of the last US closing price, Palatin, on the other hand, still has a stock market value of USD 100 million. Extremely much air upwards is thus available!
Update: Interestingly, German Merck reports today about an imminent restructuring. Coincidence?
